The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...

Not content with buying up a big chunk of the world’s generics market with its $40.5 billion merger with Actavis, Teva is muscling in on biosimilars with a deal with South Korea’s Celltrion.